

New technology leads to increased efficiency in nanoparticle development and production

## **InProcess-LSP attracts financing for market introduction of the NanoFlowSizer**

**Oss, October 1<sup>st</sup>, 2019 - The NanoFlowSizer (NFS), an innovative measuring device that improves the production process of medicine, has been introduced at the IFPAC meeting in Washington earlier this year. In order to start commercial sales of the NFS to the Process Analytical Technology (PAT) market, InProcess-LSP (Oss, the Netherlands) secured financing. BOM Brabant Ventures invests together with new investors Value Creation Capital and Mibiton to enable this introduction.**

The NFS is the first device capable of measuring nanoparticles during a manufacturing process. With the NFS scientists obtain important insights which lead to improved quality and increased efficiency of manufacturing processes, for example for nanoparticle based medicine commonly used in cancer treatment.

The market of nanoparticle medicines is growing at high rates of up to 25% annually. The interest for this novel technology therefore was substantial after the presentation of the device, earlier this year at the annual IFPAC meeting.

“A number of highly regarded industry leaders was already familiar with our technology”, says Ad Gerich, managing-director of InProcess-LSP. “Now the device is also available for sale, every manufacturer we talk to is eager to explore further what the NFS can mean to their business. There is high interest in our product from Big Pharma, as they can achieve great manufacturing benefits with our device. Other applications in which nanoparticles play a large role, such as inks, coatings, food, catalysts, etc., will also benefit from the capabilities of the NFS. The injected capital will be used to continue our product development and to introduce the NFS to our clients. We are excited that again we can count on the support of BOM and we have found an excellent balance with the addition of the expertise and strategic insights from Value Creation Capital, and the equipment investment by Mibiton.”

“The societal impact of cheaper and better medicine is a key reason for us to again invest in InProcess-LSP”, says Floris Hamel, Investment Associate Life Sciences & Medtech at BOM Brabant Ventures. “Next to the capital investment, the investors will support InProcess-LSP with the coming commercialization challenges in order to facilitate the growth of the company.”

Willem van den Berg, Managing Partner Value Creation Capital/TechNano Fund adds: “We see a large potential in the technology and product portfolio of InProcess-LSP. The vision of the management team strongly fits with the growing market for nanoparticle sizing in medical and industrial processes”.

“We are proud that Mibiton contributes to the commercialisation of the NFS by financing several systems, and thereby enabling the introduction of this promising innovation to the pharmaceutical sector”, Mibiton Investment Manager Kees Recourt adds.

-End of press release-

### **InProcess-LSP**

InProcess-LSP was founded in 2014 by three ex-MSD employees with the goal to offer process analytical services, amongst others to a solid customer base of several market leaders from the pharmaceutical industry. Since 2017 InProcess-LSP develops innovative process analytical instruments for use in the pharmaceutical, chemical and food industry amongst others. InProcess-LSP puts its knowledge and expertise to use to offer innovative and meaningful solutions concerning nano-particle sizing to become a ‘key player’ by means of their unique in-house developed technology.

For more information: <https://www.inprocess-lsp.com/>

### **BOM Brabant Ventures**

The Brabant Development Agency (BOM) is a growth accelerator. With the help of its unique knowledge and capital, BOM uses the Brabant Ventures label to focus on the accelerated and futureproof growth of ambitious Brabant startups and scale-ups in the High-Tech Systems and Software, Agrifood, Life Sciences & Health, Maintenance, Supply Chain, and Bio-based Economy top industries.

For more information: <https://www.bom.nl/brabant-ventures>

### **Value Creation Capital**

Value Creation Capital (VCC) invests in ventures active in HighTech (from the TechNano Fund), cybersecurity (from the Security of Things Fund), business software, data intelligence and IT managed services. VCC was founded in 2005 by ICT serial entrepreneurs, who successfully started, built and finally sold their fastgrowing ICT/Tech ventures. VCC distinguishes itself by combining “intellectual capital”, sector-experience and expertise, a broad network and active value creation to bring companies “to the next level”.

For more information: <https://www.valuecreationcapital.com/>

### **Mibiton**

The Mibiton foundation invests already over 25 years in Dutch Life Sciences infrastructure. These investments concern the establishment of laboratories with state-of-the-art instruments, financing of a first series of medical devices and the development of infrastructural innovations in the agrofood, pharma and industrial biotechnology sectors.

For more information: <https://www.mibiton.nl/>